Bristol-Myers Squibb ($BMY) nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use. The U.S.-based company now gains an inside track at the agency for BMS-663068, an oral "attachment inhibitor" that has demonstrated promising results in a Phase IIb trial. More from FierceBiotech